Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
Executive Summary
The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.
You may also be interested in...
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.
Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.
Merck/Roche Co-Promote Pact Attempts To Shut Vertex Out Of HCV Protease Inhibitor Space
Roche will co-promote Merck's Victrelis with its own HCV drugs Pegasys and Copegus in the U.S.